Core Viewpoint - The company, Lijun Pharmaceutical (01513), held its first extraordinary general meeting of shareholders on December 10, 2025, where it approved the nomination of Ms. Wang Zhiyao as an independent non-executive director candidate for the 11th Board of Directors [1] Group 1: Board Appointments - Ms. Wang Zhiyao was elected as an independent non-executive director, with her term starting from the date of approval until the end of the 11th Board's term [1] - The company held its first employee representative meeting on the same day, where Ms. Ran Yongmei was democratically elected as an employee representative director for the 11th Board [1] Group 2: Committee Adjustments - The company convened the 30th meeting of the 11th Board on the same day, where it approved adjustments to the members of certain specialized committees [1] - The adjusted composition of the 11th Board committees is as follows: - Audit Committee: Mr. Bai Hua (Chairman), Mr. Luo Huiyuan, Ms. Cui Lijie - Remuneration and Assessment Committee: Ms. Cui Lijie (Chairman), Mr. Bai Hua, Mr. Tang Yanggang - Nomination Committee: Mr. Luo Huiyuan (Chairman), Ms. Cui Lijie, Mr. Tao Desheng - Environmental, Social and Governance Committee: Mr. Zhu Baoguo (Chairman), Mr. Tang Yanggang, Mr. Bai Hua, Ms. Cui Lijie, Ms. Wang Zhiyao - Strategic Committee: Mr. Zhu Baoguo (Chairman), Mr. Tang Yanggang, Mr. Tao Desheng [1]
丽珠医药(01513)：选举王智瑶为独立非执行董事